Cancer Research

{
  "result": " The swarm made a critical diagnostic discovery this tick: after cataloguing 152 scientific entities, its knowledge base contained exactly zero hardened causal edges linking PCSK9 to colorectal cancer. Rather than continuing to accumulate peripheral literature, the mission executed a sharp strategic pivot, redirecting all computational bandwidth toward a tightly coordinated, three-front assault on the question of whether PCSK9 inhibition selectively matters in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal cancer.\n\nPCSK9 is best known for cholesterol regulation, but its biology may extend into cancer. Colorectal tumors are broadly split into MSS and MSI subtypes—the latter often arising from defective DNA mismatch repair—and if PCSK9 were selectively essential to one subtype, existing PCSK9-targeting drugs could potentially be repositioned. To test this, the swarm designed three orthogonal investigations. First, Mendelian randomization: using naturally occurring genetic variants near PCSK9 that alter its protein levels as natural experiments to ask whether those same variants track with MSS or MSI CRC risk in large genome-wide association studies. Second, tumor-tissue colocalization: querying CPTAC-CRC and TCGA data to see whether the genetic signal controlling PCSK9 in blood plasma also operates inside malignant colon tissue, partitioned by subtype. Third, functional genomics: mining DepMap CRISPR knockout screens to determine whether colorectal cancer cells lose viability when PCSK9 is deleted, and critically, whether that dependency differs between mismatch-repair-deficient (MSI) and proficient (MSS) lines after adjusting for technical covariates.\n\nThis tick yielded no new biological correlations; instead, its key output was surgical self-correction. The swarm identified that recent acquisitions—generic drug-repurposing reviews, bibliometric analyses, and studies of unrelated molecules such as JAK1 and HMGCR—were padding the knowledge base without advancing the core hypothesis. Those off-target entities were archived, three hypotheses were tightened to require directionally concordant evidence across both UKB-PPP and INTERVAL proteomic discovery panels before any edge can be hardened, and resources were locked onto the triad of genetic, transcriptomic, and essentiality streams.\n\nThe open questions are now precisely defined. Will a robust cis-pQTL instrument for PCSK9 survive strict colocalization against Atlantic and CPTAC plasma references? Do tumor-derived expression signals from CPTAC-CRC and TCGA confirm that the regulatory mechanism is active in cancer tissue rather than merely circulating blood? And will DepMap data reveal a statistically significant difference in PCSK9 dependency between MSI and MSS lines, with the direction of effect matching the genetic predictions? The next tick will focus on executing these analyses rather than expanding the entity list.\n\nConfidence in the *direction* of the mission has sharpened considerably even in the absence of a positive result. By refusing to harden relations on bibliometric noise and insisting on triangulation across human genetics, tumor transcriptomics, and functional genomics, the swarm has given itself the best possible chance of distinguishing a true subtype-specific liability from background noise. Whether PCSK9 emerges as a differential dependency in mismatch-repair-deficient colorectal cancer remains an open, testable question.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}